

## Board member of Biovica resigns at own request

**Biovica today announces that board member Ulf Jungnelius has resigned from the board at his own request, with immediate effect. Personal reasons are behind the decision.**

"Due to my current situation, I am unable to fully participate in the board's work in the way I would like. Therefore, I have chosen to end my assignment," said Ulf Jungnelius.

"We have great respect for Ulf's decision and thank him for his valuable contributions to Biovica," said Lars Holmqvist, Chairman of the Board of Biovica.

After Ulf Jungnelius' departure, the board will consist of six members, thus meeting the requirements of the company's articles of association

### Contact

---

Anders Rylander, CEO

Phone: +46 76 666 16 47

E-mail: [anders.rylander@biovica.com](mailto:anders.rylander@biovica.com)

Anders Morén, CFO

Phone: +46 73 125 92 46

E-mail: [anders.moren@biovica.com](mailto:anders.moren@biovica.com)

### Biovica – Treatment decisions with greater confidence

---

Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum<sup>®</sup> TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum<sup>®</sup> TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum<sup>®</sup> TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: [www.biovica.com](http://www.biovica.com)

### Attachments

---

[Board member of Biovica resigns at own request](#)